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Prediction of Distant Metastasis in Head Neck Cancer 
Patients: Implications for Induction Chemotherapy and 
Pre-treatment Staging?
Gabriela Studer1, Burkhardt Seifert2, Christoph Glanzmann1
Background and Purpose: Intensity modulated radiation therapy (IMRT) combined treatment approaches, surgical and radio-
diagnostic advances, respectively, lead to improved local-regional control in head neck cancer (HNC). With increasing local-re-
gional control, distant metastases (DM) become more meaningful. In some trials without concomitant chemotherapy, induction 
chemotherapy (IC) resulted in an absolute reduction of DM by ~10–15%. In order to define a more efficient selection of patients 
at risk for DM with respect to IC and M-staging, we analysed our patients treated by contemporary standards.
Patients and Methods: Between 1/2002 to 12/2007, 409 HNC patients were treated with IMRT; 303/409 (74%) underwent de-
finitive, 106 (26%) postoperative IMRT. The mean/median follow-up was 23/20 months (3–72). 70% tolerated 4–7, 9% 1–3 cy-
cles of simultaneous cisplatin. Treatment followed a prospectively designed protocol. In a previous study with 172 HNC IMRT 
patients, gross tumor volume (GTV) was found the strongest predictor for local-regional control. In the current study, this crite-
rion has been prospectively tested for DM. Numbers needed to treat were calculated for IC.
Results: DM developed in 28/399 (7%) patients; 10 presented initially with DM (total 38/409). In 13/28 (46%), DM remained 
the only manifestation of disease. GTV was the strongest predictor for DM (p < 0.0001) of all tested. Only 4% of patients with GTV 
< 70 cc developed DM, vs. 25% (18/73) with > 70 cc; only 6 of them (6/73, 8%) developed isolated DM.
Conclusion: GTV was the most significant predictor for DM, that could guide selective pre-treatment M-staging. The subgroup 
with isolated DM in the high risk group, that could benefit from IC, is small. 
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Voraussage der Metastasierungswahrscheinlichkeit bei Patienten mit Kopf-Hals-Tumoren: Implikationen für 
 Induktionschemotherapie und Metastasen-Staging?
Hintergrund und Ziel: Intensitätsmodulierte Radiotherapie (IMRT) zusammen mit Kombinationstherapien, chirurgischen und 
radiologischen Fortschritten führte zu Verbesserungen der Lokoregionalkontrolle bei Kopf-Hals-Tumoren (KHT), was Fernmetasta-
sierung (DM) bedeutsamer macht. In einigen Studien ohne simultane Chemotherapie resultierte die Induktionschemotherapie (IC) 
in einer absoluten DM-Reduktion von ~10–15%. Um DM-Hochrisikopatienten besser selektieren zu können hinsichtlich IC wie 
auch DM-Staging, analysierten wir unser nach modernem Standard behandeltes IMRT-Kollektiv.
Patienten und Methodik: Von 1/2002 bis 12/2007 wurden 409 KHT-Patienten kurativ IMRT-behandelt: 303/409 (74%) definitiv, 
106 (26%) postoperativ (mittlere/mediane Verlaufsbeobachtung 23/20 Monate [3–72]). 70% tolerierten 4–7, 9% 1–3 simultaner 
Cisplatin-Zyklen (Table 1). Die Therapie folgte einem prospektiv festgelegten Protokoll. In einer früheren Studie mit 172 KHT-
Patienten mit definitiver IMRT wurde das „gross tumor volume“ (GTV) als signifikantester Prädiktor für die Lokoregionalkontrolle 
nachgewiesen. In der hier präsentierten Studie wurde dasselbe volumetrische Staging-System getestet hinsichtlich dessen prä-
diktiven Wert für DM, um eine allfällige IC wie auch die initiale Metastasensuche selektiver auf ein Hochrisikopatientensegment 
beschränken zu können.
Ergebnisse: DM fanden sich bei 38/409 Patienten bzw. bei 28/399 mit initialem M0-Status (7%) (Abbildung 1, Tabelle 2); 
10 Patienten hatten initial bereits DM. Bei nur 13/28 (46%) blieben DM die einzige Krankheitsmanifestation. Das GTV erwies sich 
als signifikantester aller getesteter Metastasenprädiktoren (p < 0,0001, Abbildung 2, Tabelle 3); nur 4% der Patienten mit einem 
GTV < 70 cc entwickelten DM, vs. 25% (18/73) mit GTV > 70 cc, von diesen nur 6 mit isolierter DM (6/73, 8%).
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Introduction
Clinical implementation of intensity modulated radiation 
therapy (IMRT), together with combined treatment ap-
proaches in definitive and postoperative treatment settings, 
surgical and radio-diagnostic advances, respectively, lead to 
an encouraging improvement of the loco-regional control in 
head and neck cancer (HNC) during the last years. When 
compared with the combined treatment arm of two prospec-
tive randomized trials from the near past with conventional 
irradiation (non IMRT), our IMRT cohort [26] showed an im-
provement of 3-year local-regional and overall survival rates 
of ~ 20% each (~ 70 vs. ~ 50%, and ~ 80 vs. ~ 60% [3, 14] 
 respectively). This tendency results in a long term survivor 
population, for which distant metastasis (DM) may become 
more meaningful [30]. 
In some trials, induction chemotherapy (IC) has shown to 
achieve an absolute reduction of DM of ~ 10–15% [1], [Posner 
MJ: Educational book ASCO 2006]; IC is recently getting an 
issue of growing interest. However, its additional risks, mainly 
of limiting haematological reserves with respect to the follow-
ing standard concomitant chemo-radiation, should not be un-
derestimated. Risk prediction for DM could help to select and 
estimate the number of patients, who could benefit of IC.
A second point on which prediction of DM could have an 
impact on is pre-treatment search for metastasis. DM in HNC 
is a relatively rare event. Many patients with an a priori low 
probability for DM have to undergo staging examinations.
Aim of this study was to prospectively identify character-
istics of HNC patients at high risk for DM, to achieve a more 
efficient selection of patients with respect to IC and M-stag-
ing. 
Patients (Table 1) 
Between 1/2002 and 12/2007, 409 HNC patients have been 
treated with IMRT for squamous cell carcinoma (SCC, n = 
389) or lymphoepithelial carcinoma (n = 20) at the Depart-
ment of Radiation Oncology, University Hospital Zurich 
(USZ). In 2002, only local-regionally advanced oropharynx 
tumor patients have been treated with IMRT; since 2003, all 
HNC patients (except of some early glottic tumor patients) 
were consecutively included in our IMRT program. 
303/409 patients underwent definitive IMRT (dIMRT, 
74%), 106 were referred for postoperative IMRT (pIMRT, 
26%). Tumor sites were oropharynx (40%), oral cavity (19%), 
hypopharynx (15%), larynx (12%), nasopharynx (10%), and 
paranasal sinus (2%). The mean/median follow up time was 
23/20 months (3–72). In 70% of all patients, 4–7 cycles of si-
multaneous cisplatin (40 mg/m2/w) were given, 9% tolerated 
1–3 cycles. In 16%, no chemotherapy was added, mainly due 
to co-morbidity or age. In 22 patients (5%), concomitant 
Schlussfolgerung: Das GTV war der signifikanteste Voraussageparameter für DM, und könnte als Selektionsparameter für die 
prätherapeutische DM-Suche dienen. Die Subgruppe mit isolierter Metastasierung in der Hochrisikogruppe, die von einer IC pro-
fitieren könnte, ist klein (Tabelle 4). 
Schlüsselwörter: Fernmetastasen bei Kopf-Hals-Tumoren · Prognostische Faktoren für Metastasierung · Volumetrisches 
Staging 
Table 1. Demographic information and clinical-pathological character-
istics of the assessed cohort (n = 409). IMRT: intensity modulated ra-
diotherapy; SCC: squamous cell carcinoma; CDDP: cisplatin; tGTV: total 
gross tumor volume; NA: not assessable; FU: follow-up.
Tabelle 1. Demographische Informationen und klinisch pathologische 
Charakteristika der untersuchten Kohorte (n = 409). IMRT: intensitäts-
modulierte Radiotherpie; SCC: Plattenepithelkarzinom; CDDP: Cispla-
tin; tGTV: Gesamttumorvolumen;  NA: nicht vorliegend; FU: Follow-up. 
Parameters Definitive IMRT Postoperative IMRT
N  303 (74%) 106 (26%)
Gender (m : f) 236 : 67 84 : 22
Mean age (range) 60 (21–87) 60 (32–85)
Diagnoses
Oropharynx 125 39
Oral cavity 34 45
Hypopharynx 57  6
Larynx 41  7
Nasopharynx 39  0
Sinonasal  5  4
Unkown SCC primary  1  5
T stages
Tx  1  (3%)  5 (5%)
T1 23  (7%) 24 (22%)
T2 97 (32%) 31 (29%)
T3 61 (20%)  7 (7%)
T4 98 (32%) 17 (16%)
Recurrence 23  (8%) 22 (21%)
N stages
N0 49 (16%) 21 (20%)
N1 40 (13%) 11 (10%)
N2a/b 85 (28%) 48 (45%)
N2c 98 (32%) 11 (10%)
N3 16 (5%)      6 (5%)
Recurrence 15 (5%)    9 (8%)
Concomitant chemotherapy 
None  43 (14%) 23 (22%)
1–3 cycles CDDP  28 (9%)  7 (7%)
4–7 cycles CDDP 216 (71%) 70 (66%)
Cetuximab  16 (5%)  6 (5%)
tGTV  57 NA
16–70 cc 173 NA
> 70 cc  73 NA
Mean FU (range, mo.) 22.6 (3–72) 20.1 (3–64)
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 cetuximab was given instead of cisplatin. All but 2 NPC pa-
tients underwent 1–3 cycles of cisplatin/5-fluorouracil (5-FU) 
3–6 weeks following concomitant cisplatin-IMRT.
Methods 
In a former evaluation, based on 88 retrospectively and 84 
prospectively analysed patients (treated 01/2002–12/2004 
and 01–11/2005; n total = 172, in this recent study included), 
a volumetric staging system (VSS) was found the most im-
portant predictor of local-regional outcome [28]. This VSS 
bases on two cut-offs: primary or total gross tumor volume 
(GTV): 1–15 cc (favourable) vs. 16—70 cc (intermediate) vs. 
> 70 cc (unfavourable). While the primary GTV was used to 
predict local control rates, the total GTV was shown to best 
predict nodal control rates, disease free, and overall survival, 
respectively. 
This volumetric criterion has since been applied prospec-
tively in definitive IMRT patients (no GTV measurable in 
planning computed tomography [CT]) of operated patients), 
with respect to its predictive value for DM. 
In addition, analyses taking the UICC (Union Interna-
tional Contre le Cancer) TNM criteria were performed, and 
the impact of treatment sequence, primary site, gender, and 
age as potential prognostic factors for DM, have been as-
sessed. The recent study presents these results and its poten-
tial implications on clinical decisions. 
All patients have been irradiated using IMRT with simul-
taneously integrated boost (SIB) technique [25], using dIMRT 
schedules with 33 × 2.11 Gy to the boost planning target vol-
ume (boost PTV), or, – as a mild dose escalation –, with 33 × 
2.2 Gy to large GTVs, or with 35 × 2.0 Gy to the boost PTV in 
patients with central nervous structures in the PTV, or with 
substantial parts of the larynx involved. The pIMRT schedule 
provided 30–33 × 2.0 Gy to the boost PTV. The elective dose 
was 54 Gy in most patients, intermediate doses of 60–66 Gy 
were delivered depending on individual risk.
All but 8 patients are in a regular follow up program in 
our HNC joint centre clinic or maxillofacial surgery clinic at 
the USZ. Routine tests  included, besides the history, physical 
examination and endoscopy of the pharyngo-laryngeal region. 
If these tests were of no evidence of disease, usually no further 
tests were done but a CT scan or magnetic resonance imaging 
at 1 year post-treatment in the majority of patients.
Statistics
Survival data were calculated using Kaplan-Meier curves and 
log-rank tests implemented in StatView® (Version 4.5). Pro-
portions were compared using the Chi-square test. p values 
< 0.05 were considered statistically significant. Univariate and 
multivariate analyses were performed with a Cox proportional 
hazards regression model in StatView®.
Results 
3-year local and nodal control rates, disease free, and overall 
survival of the entire cohort were 80, 87, 73, and 80%, respec-
tively. 74% of all patients were alive with no evidence of dis-
ease when last time seen.
A recent update of the definitive IMRT cohort using VSS 
shows 3-year local control rates of 93 vs. 78 vs. 50% for pri-
mary GTV 1–15 cc vs. 16–70 cc vs. > 70 cc, respectively (p < 
0.0001); the corresponding disease free survival rates are 82 vs. 
70 vs. 55% (p = 0.0002), the overall survival rates are 88 vs. 75 
vs. 65% (p = 0.13). 
Distant metastasis (DM, Figure 1, Table 2) was diagnosed 
in 38 of all 409 patients (9%); 10/38 presented with initial DM, 
resulting in a DM rate of 7% (28/399) in initially M0 patients. 
15/38 patients with DM died after mean/median 16/12 months 
(3–40) after completion of IMRT; mean/median survival time 
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Table 2. Characteristics of distant metastasis (DM) patients. LF: local 
failure; NF: nodal failure. TU: tumor.
Tabelle 2. Charakteristika der Untergruppe mit Fernmetastasen (DM). 
LF:  lokales Rezidiv; NF: nodale Metastasierung; TU: Tumor.
Parameters n (%)
Distant Metastasis (DM) 38/409 (9)
DM only 13/38   (34)
DM +  LF  8/38 (21)
DM +  NF  5/38 (13)
DM +  LF + NF 12/38  (26)
DM +  2nd TU  4/38 (11)
DM at initial diagnosis 10/38 (26)
DM sequence
DM together with LF/NF 14/25 (56)
DM > 6 months prior to LF/NF  2/25 (8)
DM > 6 months post LF/NF  5/25 (25)
Figure 1. 3-year distant control rate in 409 patients with intensity mod-
ulated radiation therapy (IMRT).
Abbildung 1. Metastasenfreies 3-Jahres-Überleben bei 409 Patienten 
mit intensitätsmodulierter Radiotherapie (IMRT).
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of still alive 23 patients at the time point of study analysis was 
23/23 months (4–47). The 2-year overall survival rate was 52% 
in patients with DM, 90% in DM free patients, respectively 
(p < 0.0001). 6 of 10 patients with DM at initial diagnosis died 
mean 21 months (4–40) after completion of IMRT, 4/10 were 
alive when last time seen, mean 14 months (4–42) after IMRT. 
In only 3/38 patient, DM was diagnosed later than 12 months 
following completion of IMRT. Pre-treatment WHO perfor-
mance status was 0 in 23, 1 in 15 of the 38 DM patients. The 
lung was the most frequent site of metastasis (33/38, 87%). In 
13/28 (46%) of metastasised initially M0 patients, DM re-
mained the only manifestation of disease; 7 of these 13 died of 
DM mean/median 17 months (9–36) post-treatment, 6 are still 
alive, mean 18 months post-treatment (3–43). There were no 
characteristic features detectable in this ‘DM only’ subgroup, 
compared with local-regional failure DM patients. 
Predictive Factors for DM (Figure 2, Table 3)
The pre-therapeutic GTV revealed to be the strongest predic-
tive factor for DM in definitively irradiated patients with mea-
surable primary or total GTV (p < 0.0001 each, (Figure 2) out 
of all assessed potentially predictive parameters. Only 9/230 
patients (4%) with a total GTV < 70 cc developed DM, vs. 
18/73 patients (25%) with total GVT > 70 cc. In uni- and mul-
tivariate analysis, the T- and N-systems were not significantly 
predicting the DM probability but in the constellation of local-
regionally advanced stages (≥ T3N2b) and N0–1 vs. N > 1 
(Table 3). Treatment sequence was not related to the DM rate 
(11/106 postoperative [10%] vs. 27/303 [9%] definitive IMRT 
patients). The site of primary was not a statistically significant 
predictor. DM was found in 6% of hypopharynx, 7% of oro-
pharynx, 8% of oral cavity, 10% of nasopharyngeal cancer 
(NPC), and 14% of laryngeal tumors, respectively. Separate 
analyses showed no difference to the non-NPC cohort with 
respect to the DM rate (4/39 NPC [10%], 24/269 non-NPC 
[9%]; 3-y distant control 86% each). Age was not a significant 
factor neither, with mean 60.7 vs. 60.5 years in the DM vs. dis-
tantly controlled group. 
All but one distant event occurred in men, however, 26% 
(61/236) of all male patients presented with a total GTV > 70 
cc (i.e. ‘at risk’ for DM), while this was the case in only 12% 
(8/67) of females (p = 0.059, Chi-square proportion test). A 
retrospective analysis of the impact of cisplatin on DM showed 
no difference between patients with no chemotherapy vs the 
ones with 1–3 vs. 4–7 cycles, however, this is of limited value, 
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Table 3. Potentially predictive parameters for distant metastasis (DM):  p-values. 26 and 25% of patients with primary gross tumor volume (pGTV) 
or total GTV (tGTV) > 70 cc, respectively, developed DM. DC:  without distant metastasis. 
Tabelle 3. Potenzielle prädiktive Faktoren für Fernmetastasierung (DM): p-Werte. 26 und 25% der Patienten mit Primärtumorvolumen (pGTV) oder 
Gesamttumorvolumen (tGTV) > 70 cc entwickelten DM. DC: frei von Fernmetastasen. .
Parameters N patients p - value DM (%) 3y DC (%)
Tx sequence (postoperative vs. definitive IMRT)  0.98
Simultaneous Cisplatin (none vs. 1–3 vs. 4–7 cycles)   0.39
Diagnosis   0.29
T  0.36
T1,2 vs. T3,4, reccurence  0.19
T1–2 N0–2b vs. all others  0.25
N  0.23
N0–1 vs.  > N1 122 / 261 0.04 5 vs. 12 93 vs. 88
≥ T3N2b vs. all others 127 / 276 0.007 14 vs. 7 84 vs. 91
pGTV (1–15 cc vs. 16–70 cc vs. > 70 cc) 104 / 150 / 40 < 0.0001 6 vs. 6 vs. 26 92 vs. 92 vs. 67
tGTV (1–15 cc vs. 16–70 cc vs. > 70 cc) 57 / 173 / 73 < 0.0001 2 vs. 7 vs. 25 98 vs. 95 vs. 67
tGTV < 70 cc/anyN vs. tGTV > 70 cc+ ≥ N2b 223 / 59 < 0.0001 4 vs. 23 95 vs. 70 
tGTV < 70 cc/anyN vs. tGTV > 70 cc+ < N2b   223 / 15 < 0.0001 4 vs. .20 95 vs. 70
Figure 2. Distant control rate, analysed according to the total gross tu-
mor volume (tGTV), measured in 303 patients with definitive intensity 
modulated radiation therapy (IMRT) (cut off values 15 and 70 cc).
Abbildung 2. Metastasenfreies Überleben, analysiert nach dem Ge-
samttumorvolumen (tGTV) bei 303 Patienten mit definitiver intensi-
tätsmodulierter Radiotherapie (IMRT) (Schnittstellen: 15 und 70 cc).
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as the subgroup with no or few cycles of cisplatin is character-
ized by elderly or co-morbid patients. 
14% of patients (59/409) were diagnosed for a second or 
even third or forth primary prior or following IMRT, 4 of them 
belonged to the DM subgroup.
Discussion
The observed low DM incidence rate of 7% (28/399 patients 
with initial M0-status, (Figure 1) is concordant with that of re-
cent reports in the IMRT literature, ranging between ~ 8–12% 
(> 90% 3y DM-free survival) [4, 6, 19, 30] following IMRT-che-
motherapy, and seems to be lower than many published values 
following conventional radiation techniques, with ~ 8–25% of 
DM [1, 2, 3, 8, 11, 14, 24]. A relation between increasing local-
regional tumor control rates following IMRT and this tendency 
to decreasing DM rates can not be excluded.
Associations between various factors like primary site, 
regional extension (TN-stage), grading and others, and the 
rate of DM have been reported [2, 12, 15, 20, 23, 24, 30].
In our cohort, GTV was the strongest statistically signifi-
cant predictor for DM (Table 3). Tumor volume has formerly 
been reported as a statistically significant factor for DM in HNC 
by Chao et al. [4] (as well as for other tumors [29]). As far as we 
know, the here presented study is the first attempt to use a VSS 
with defined predictive cut off values for DM prediction. The 
tested VSS has been reported as a highly reliable tool to predict 
local-regional outcome [28], and could herewith been con-
firmed as similarly reliable in predicting DM (Figure 2). 
Our N0–1 vs. N > 1 nodal subgroups showed a less strong 
but significant difference in predicting DM (p = 0.04), while 
N-status itself was not significant (yet), likely due to the small 
number of events per N-stage, and maybe also due to the fact 
that not all lymph nodes considered as ‘tumor affected’ have 
been histopathologically confirmed. Even 
if the difference was statistically signifi-
cant, the percentage difference of DM 
was low (5 vs. 12%, (Table 3), and there-
fore this criterion not too helpful as prog-
nostic selection tool. Similarly, the com-
bination of advanced TN stages resulted 
in a ratio of only 14% vs. 7% DM. The 
‘risky’ constellation ‘tGTV > 70 cc plus 
advanced N status ≥ N2b’ revealed to be 
equal to the constellation  ‘tGTV > 70 cc 
plus early N status < N2b’, compared to 
‘tGTV < 70 cc plus any N’ (23 and 20 vs. 
4% DM), showing the superiority of the 
volumetric over the nodal criterion (Ta-
ble 3, grey field).
The site of the primary may influ-
ence the rate of DM, with reported ~ 75–
80% 2–3y DM-free survival rates in local-
regionally advanced nasopharyngeal [16, 
18, 21, 29], sinonasal [9, 13, 22], hypopha-
ryngeal [27] and laryngeal tumors  [5], ~ 85–95% in oropharyn-
geal tumors  [4, 7, 15], and ~ 90–95% in oral cavity cancer (OCC) 
[3–6, 10], respectively. For local-regionally advanced hypopha-
ryngeal tumors, 3y-DM free survival rates of as low as 30% are 
reported [8, 17]. Comparisons of DM rates between the studies 
are difficult due to a wide range of treatment approaches, stag-
ing examinations, and treatments. In our population, no signifi-
cant primary site related difference was found, likely due to 
imbalanced samples with low numbers of events per entity; with 
respect to the equal DM rate in NPC and non-NPC, one has to 
consider the different treatment, with additional post-radio-
chemotherapeutic chemotherapy (cisplatin/5-FU) in NPC, ac-
cording to the standard. 
All but one patient with DM were men. However, consid-
ering that 62/236 dIMRT treated male patients presented with 
a tumor volume > 70 cc (26%), while this was the case in only 
8/67 women (12%, i.e. 2-times less large tumors in women), 
this has to be taken with caution. 
Potential Consequences of  Volumetric DM Prediction
One quarter of patients with GTV > 70 cc presented with DM 
at diagnosis or during the first 12 months from treatment start, 
while only 4% with GTV < 70 cc. Volumetric staging may 
serve as selection tool to detect high risk patients for DM with 
respect to the question of IC. In some randomised earlier tri-
als, adjuvant chemotherapy in patients with locally advanced 
HNC showed a reduction of DM from ~ 25–15%, a relative 
reduction of approximately 40%. We consider this observa-
tion as helpful information in discussing IC. 
For various subgroups at risk, the number needed to treat 
(NNT) has been calculated (Table 4): the NNT was lowest for 
the volumetric criterion (factor 1.5 to ~ 3), the absolute num-
ber of patients who may profit from IC is small. 
Table 4. Induction chemotherapy (IC): number needed to treat (NNT) in various subgroups at 
risk. tGTV: total gross tumor volume (in 303 patients with definitive intensity modulated radio-
therapy). DM: distant metastatsis.
Tabelle 4. Induktionschemotherapie: „number needed to treat“ (NNT) für diverse Risikogrup-
pen. tGTV: Gesamttumorvolumen (bei 303 Patienten mit definitiver intensitätsmodulierter 
Radiotherapie). DM: Fernmetastasen.
Subgroups at risk n/N Patients n Distant failure  Absolute reduction (%)  NNT
 (%) (%) of DM (based on 40% 
   relative risk reduction)
T3/4 or recurrence 219/399 16 7.3–4.4  34
 (55) (7)
> N2a or recurrence 260/399 23 8.8–5.3 29
 (65) (9)
T3/4N2b–3 or recurrence 120/399 13 10.8–6.5 23
 (30) (11)
tGTV > 70cc 68/295 13 19.1–11.5 13
 (23) (19)
All  399/399 28 7.0–4.2 36
 (100) (7)
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There is still a certain probability that IC could also be 
loco-regionally effective, however, hardly by a similar factor 
than concomitant radio-chemotherapy is. 
With respect to pre-therapeutic M-staging with PET(CT), 
VSS would similarly allow to narrow DM search to a subgroup 
of high risk for DM. Considering that findings of ‘small/limit-
ed/suspected’ DM at diagnosis do often not change our local-
regional treatment approach (i.e., patients with initially diag-
nosed limited DM and local-regionally disease considered as 
‘curable’, underwent IMRT with ‘local-regionally curative’ in-
tention), one could even provide to confine M-staging to the 
few patients with local-regionally as ‘hardly curable’ stated 
disease, in order to use PETCT to ease the decision for pallia-
tive treatment. 
VSS may therefore translate into therapeutic and/or diag-
nostic consequences.
Conclusion
GTV was the most significant predictor for DM, revealing 
DM in one quarter of patients with GTV > 70 cc vs. < 5% in 
patients with GTV < 70 cc, respectively. These finding could 
translate into a more rationale and selective pre-treatment M 
staging, and consideration of induction chemotherapy con-
fined to patients at high risk. These are the same patients who 
could benefit from an improvement of local-regional control. 
However, even in the DM high risk group, the subgroup with 
isolated DM, that could benefit from IC, is small.
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